ELITE PHARMACEUTICALS INC /DE/

ELITE PHARMACEUTICALS INC /DE/ insiders are currently net buyers of ELI stock, showing neutral sentiment over the past 90 days. Executives have purchased $191.3K while selling $162.4K, resulting in a positive net flow of $28.9K. This buying activity represents 54% of total transaction volume.

ELITE PHARMACEUTICALS INC /DE/ has 6 active insiders who have filed SEC Form 4 transactions in the past 90 days. Charan Behl (Executive) leads with 27 transactions totaling $116.8K. Partners Lp Trellus (Executive) follows with 3 transactions worth $114.8K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. ELITE PHARMACEUTICALS INC /DE/'s current score of 54/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $191.3K in purchases and $162.4K in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Jul 21, 2009, when Company, Llc Trellus Management (Executive) disposed of 138,528 shares at $0.06 per share for $8.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ELI insider trading sentiment is currently neutral with an Alignment Score of 54/100. The balanced activity—$191.3K bought vs $162.4K sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like ELITE PHARMACEUTICALS INC /DE/. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ELI, we track all Form 4 filings—currently showing 45 transactions from 6 insiders over 90 days.

A 10b5-1 plan allows ELITE PHARMACEUTICALS INC /DE/ executives to pre-schedule stock sales when they don't possess material non-public information. At ELI, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ELI appears discretionary, making insider signals more meaningful.

You can monitor ELITE PHARMACEUTICALS INC /DE/ (ELI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 6 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. ELITE PHARMACEUTICALS INC /DE/'s current score of 54/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $191.3K in purchases versus $162.4K in sales over 90 days, resulting in a net flow of $28.9K.

SEC Form 4 filings are mandatory reports that ELITE PHARMACEUTICALS INC /DE/ insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ELI, the most common type is "P" with 38 occurrences. The most recent Form 4 was filed on Jul 21, 2009 by Company, Llc Trellus Management.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At ELITE PHARMACEUTICALS INC /DE/, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ELI represents discretionary decisions with more informational value.